Kristoffer Watten Brudvik1,2, Lars Thomas Seeberg3,4, Harald Hugenschmidt3, Anne Renolen5, Cecilie Bendigtsen Schirmer5, Cathrine Brunborg6, Bjørn Atle Bjørnbeth7,3, Elin Borgen5, Bjørn Naume8,9, Anne Waage7, Gro Wiedswang3. 1. Department of Hepato-Pancreatico-Biliary Surgery, Oslo University Hospital, Oslo, Norway. kristoffer@brudvik.dk. 2. Department of Gastrointestinal Surgery, Oslo University Hospital, Oslo, Norway. kristoffer@brudvik.dk. 3. Department of Gastrointestinal Surgery, Oslo University Hospital, Oslo, Norway. 4. Department of Gastrointestinal Surgery, Vestfold Hospital Trust, Tønsberg, Norway. 5. Department of Pathology, Oslo University Hospital, Oslo, Norway. 6. Department of Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway. 7. Department of Hepato-Pancreatico-Biliary Surgery, Oslo University Hospital, Oslo, Norway. 8. Department of Oncology, Oslo University Hospital, Oslo, Norway. 9. Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Abstract
BACKGROUND: The presence of circulating tumor cells (CTCs) is negatively associated with survival after resection of colorectal liver metastases (CLM). The current study aimed to determine the prognostic value of CTCs and disseminated tumor cells (DTCs) at the time of surgery and the prognostic value of CTCs at follow-up assessment, for patients scheduled to undergo two-stage hepatectomy with portal vein embolization (PVE) for CLM. METHODS: Samples were collected at surgery (blood and bone marrow) and at follow-up assessment (blood) for the period 2008 through 2011. In this study, CTCs were detected with the CellSearch system, and DTCs were detected using standard immunocytochemical analysis. RESULTS: Of 24 patients, 18 completed both stages, and no patients were lost to follow-up. The median overall survival (OS) was 37 months, and the median recurrence-free survival (RFS) was 7 months. At surgery, CTCs were found in nine patients (38 %), and their presence was associated with reduced OS (p < 0.001) and RFS (p = 0.006). Follow-up CTC status was available for 11 patients. All eight patients with positive CTC status experienced recurrence. Two of three patients with negative CTC status remained recurrence free. In seven patients (32 %), DTCs were detected but were not associated with OS or RFS. CONCLUSIONS: The presence of CTCs at surgery is associated with worse OS and RFS for patients undergoing two-stage hepatectomy with PVE for CLM. Analysis of CTCs should be explored further for their potential to assist in treatment decisions and monitoring for CLM patients.
BACKGROUND: The presence of circulating tumor cells (CTCs) is negatively associated with survival after resection of colorectal liver metastases (CLM). The current study aimed to determine the prognostic value of CTCs and disseminated tumor cells (DTCs) at the time of surgery and the prognostic value of CTCs at follow-up assessment, for patients scheduled to undergo two-stage hepatectomy with portal vein embolization (PVE) for CLM. METHODS: Samples were collected at surgery (blood and bone marrow) and at follow-up assessment (blood) for the period 2008 through 2011. In this study, CTCs were detected with the CellSearch system, and DTCs were detected using standard immunocytochemical analysis. RESULTS: Of 24 patients, 18 completed both stages, and no patients were lost to follow-up. The median overall survival (OS) was 37 months, and the median recurrence-free survival (RFS) was 7 months. At surgery, CTCs were found in nine patients (38 %), and their presence was associated with reduced OS (p < 0.001) and RFS (p = 0.006). Follow-up CTC status was available for 11 patients. All eight patients with positive CTC status experienced recurrence. Two of three patients with negative CTC status remained recurrence free. In seven patients (32 %), DTCs were detected but were not associated with OS or RFS. CONCLUSIONS: The presence of CTCs at surgery is associated with worse OS and RFS for patients undergoing two-stage hepatectomy with PVE for CLM. Analysis of CTCs should be explored further for their potential to assist in treatment decisions and monitoring for CLM patients.
Authors: Guido Torzilli; René Adam; Luca Viganò; Katsunori Imai; Jeremias Goransky; Andrea Fontana; Christian Toso; Pietro Majno; Eduardo de Santibañes Journal: Liver Cancer Date: 2016-11-29 Impact factor: 11.740
Authors: Lars Thomas Seeberg; Cathrine Brunborg; Anne Waage; Harald Hugenschmidt; Anne Renolen; Ingunn Stav; Bjørn A Bjørnbeth; Elin Borgen; Bjørn Naume; Kristoffer W Brudvik; Gro Wiedswang Journal: Ann Surg Oncol Date: 2017-03-03 Impact factor: 5.344
Authors: Lai Jiang; Jian-Guo Feng; Gang Wang; Yu-Ping Zhu; Hai-Xing Ju; De-Chuan Li; Yong Liu Journal: Transl Cancer Res Date: 2020-03 Impact factor: 1.241